**DRUG THERAPY DAY**



**Wednesday, June 12, 2024**

**0800-1530**

**Four Points by Sheraton London, 1150 Wellington Rd**.

***Presented by the Division of Clinical Pharmacology and Toxicology***

Overall Conference Learning Objectives:

By the end of this program, participants will be able to:

1. Describe therapeutic issues of relevance for drug treatments for children and teenagers
2. Assess the benefits and limitations of medications for common conditions (e.g. hypertension, dyslipidemia) in patients with chronic kidney disease
3. Discuss medications frequently used in elderly patients
4. Review current pharmacology topics, such as interventions for smoking cessation and rational antibiotic use

**AGENDA**

08:15 – 08:45 Registration, Coffee/Tea and Light Refreshments

08:45 – 09:00 Welcome and Opening Remarks: Dr. Facundo Garcia-Bournissen

Session 1 – Paediatrics – Therapeutic Issues in Drug Treatment for Pregnant Women and Children

**Moderator: Dr. Facundo Garcia-Bournissen,** *Department of Paediatrics, London Health Sciences Centre*

|  |  |
| --- | --- |
| Time | Topic/Speaker |
| 09:00 - 09:20 | **Past, present and future of drug therapy in Children with Atopic Dermatitis** – Dr. Blanca Del Pozzo, Department of Paediatrics  Objectives:   1. Describe the most common therapeutic options for the management of atopic dermatitis in children 2. Assess the potential adverse events associated with atopic dermatitis treatment |
| 09:20 – 09:40 | **Approach to mood and anxiety in Adolescents**- Dr Mariano Macias, Department of Paediatarics and Adolescent Medicine  Objectives:   1. Recognize and diagnose common mood and anxiety disorders in the adolescent population. 2. Identify the etiology and risk factors for mood and anxiety in adolescents. 3. Describe evidence-based therapeutic approaches, including psychotherapy and pharmacological treatment. |
| 09:40 – 10:00 | **Treatment of ADHD in Young Adults** – Dr. Josh Howie, Division of Clinical Pharmacology  Objectives:   1. Recognize the importance of ADHD treatment 2. Appraise treatment options in ADHD. |
| 10:00 – 10:20 | **Safety of medications during breastfeeding** - Dr. Facundo Garcia-Bournissen, Department of Paediatrics  Objectives:   1. Illustrate the general principles on how to judge infant risks of maternal medications during breastfeeding 2. Review specific medications that may be concerning during breastfeeding 3. Discuss commonly used therapeutics that are compatible with breastfeeding |
|  |  |

**10:20 – 10:40 Nutrition Break**

Session 2 – Renal/Nephrology

**Moderator: Dr. Daniel Hackam,** *Division of Clinical Pharmacology, London Health Sciences Centre*

|  |  |
| --- | --- |
| Time | Topic/Speaker |
| 10:40 – 11:00 | **SGLT2 inhibitors: Game changers in chronic kidney disease (CKD)** – Dr. Louise Moist, Division of Nephrology  Objectives:   1. Review the evidence to support the use of SGLT2 inhibitors in patients with CKD 2. Evaluate the relationship between the heart and the kidney and the benefits of SGLT2 inhibitors 3. Discuss how to effectively treat CKD patients with SGLT2 inhibitors |
| 11:00 - 11:20 | **Hypertension Management in Patients with Chronic Kidney Disease** – Dr. Matt Weir, Division of Nephrology  Objectives:   1. Recognize how to select anti-hypertensive medications for patients with CKD 2. Review evidence on adverse events related to these medications |
| 11:20 - 11:40 | **DOACs in Chronic Kidney Disease** – Sabih Jamil, Pharmacy Services, London Health Sciences Centre  Objectives:   1. Appraise the impact of Chronic Kidney Disease (CKD) on anticoagulation. 2. Assess the evidence for DOACs in CKD and analyze their safety and efficacy profiles in this patient population. 3. Describe the factors influencing the choice of anticoagulant and dosing adjustments in CKD patients. 4. Evaluate the bleeding risk associated with DOACs in CKD and review available reversal agents in case of bleeding events. |
| 11:40 – 12:00 | **Dyslipidemia in Chronic Kidney Disease** – Dr. Steven Gryn, Division of Clinical Pharmacology  Objectives:   1. Review the role for lipid lowering therapies in patients with chronic kidney disease 2. Evaluate special considerations for drug choice and dosing in patients with chronic kidney disease |

***12:00 noon – 1:00 PM Lunch***

Session 3 – Keynote Speaker

**Moderator: Dr. Michael Rieder**, Department of Paediatrics

|  |  |
| --- | --- |
| Time | Topic/Speaker |
| 1:00 - 1:35 | **Optimizing multimorbidity and polypharmacy: Geriatric Clinical Pharmacology Beyond "Starting Low and Going Slow”** – Dr. Joanne Ho, Associate Professor, Geriatric Medicine, Clinical Pharmacology and Toxicology, DeGroote School of Medicine, McMaster University; Schlegel Chair in Geriatrics and Pharmacotherapy, Research Institute for Aging; Co-Executive Director, GeriMedRisk; Head of Service, Geriatric Medicine, Grand River Hospital and St. Mary's General Hospital  Objectives:   1. Review the epidemiology of adverse drug events among older adults 2. Describe age-related changes in pharmacology 3. Appraise interventions to decrease the risk of adverse drug events among older adults |

**1:35 – 1:55 Nutrition Break**

Session 4 – Therapeutic Updates

**Moderator: Denise Keller**, Pharmacy Services, London Health Sciences Centre

|  |  |
| --- | --- |
| Time | Topic/Speaker |
| 1:55 - 2:10 | **Insomnia in the Elderly** – Dr. Jennie Wells, Division of Geriatric Medicine  Objectives:   1. Describe the safety issues with “**Z** drugs”, ben**Z**odiazepines, and Tra**Z**odone 2. Assess the mechanism and use of Orexin receptor antagonists |
| 2:10 - 2:25 | **Alcohol-associated Liver Disease** – Dr. JP Arab, Division of Gastroenterology and Hepatology and Department of Epidemiology and Biostatistics  Objectives:  1. Summarize the current treatments for alcohol-associated liver disease  2. Assess the use of steroids in severe alcohol-associated hepatitis (AH)  3. Discuss novel treatments for ALD/AH |
| 2:25 - 2:40 | **Immunization Insights: Unraveling Arexvy** – Dr. Huma Saeed, Division of Infectious Disease  Objectives:   1. Review epidemiology of RSV 2. Assess efficacy and safety of vaccine 3. Describe recommendations in high-risk patient populations 4. Discuss future directions |
| 2:40 – 2:55 | **Shorter is Better:  An evidence-based case for shorter antibiotic courses to treat common infections** – Amy Aasen, Pharmacy Services, London Health Sciences Centre  Objectives:   1. Describe the potential harms associated with continuing antibiotic therapy for longer than the duration required for therapeutic efficacy. 2. Summarize the evidence base supporting shorter therapy durations for acute bacterial skin and skin structure infections. |
| 2:55 – 3:10 | **Vaping, the new smoking** – Tom Kontio, Thames Valley Family Health Team and Pharmasave Pharmacy  Objectives:   1. Describe the scope of vaping in the general population 2. Review therapeutic interventions to address cessation where vaping and cigarettes are both consumed |
| 3:10 – 3:30 | **Closing remarks and completion of the program evaluation** |

**Non-Financial Sponsorship Statement -** This program has received no financial support.

**25% of this program is dedicated to participant interaction**.

Course Credits:

**CFPC (Mainpro+ Certification)**

**This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University for up to 4.5 Mainpro+ credits.**

**For RCPSC (MOC Section 1)**

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of **4.5 hours** (credits are automatically calculated).

**Each** participant should claim only those hours of credit that he/she actually spent participating in the educational program.

Conference Site

Four Points by Sheraton located at 1150 Wellington Rd. London, Ontario. Parking is available on site (free of charge). Please park at the rear of the main building.

Registration

To register on-line: <https://www.schulich.uwo.ca/clinpharm/about_us/news/2024/drug_therapy_day_2024.html>

Early Bird Registration $160.00 (before May 1, 2024)

After Early Bird Registration $180.00 (before June 5, 2024)

Trainee (with proof) $75.00

Onsite Registration (limited to 10 attendees) $225.00